Neurology · 1993 · 158 citations · 0 references
MedicinePharmacologyPharmacotherapyMovement DisordersNeuropharmacologyPsychopharmacologyAntidepressant PharmacologyAntidepressant PharmacotherapyAntidepressant TherapyDopaminergic PharmacologyParkinson DiseaseParkinsonian DisordersAntidepressant EfficacyAntidepressant ResponseDisability ReductionDopamine-related Movement DisordersParkinson's Disease PharmacotherapyParkinson’s Disease PharmacotherapyParkinson’s Disease Treatment
Depression is a major clinical feature of Parkinson's disease. We report the increased amount of motor disability in four patients with idiopathic Parkinson's disease after exposure to the antidepressant fluoxetine. The possibility of a clinically relevant dopamine-antagonistic capacity of fluoxetine in Parkinson's disease patients must be considered.